Invivyd Inc (IVVD)

$2.38 -0.13 (-5.18%)
Market Cap 585.14M
Revenue (ttm) 25.38M
Net Income (ttm) -169.93M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -669.54%
Debt to Equity Ratio 0.00
Volume 3,352,300
Avg Vol 8,406,424
Day's Range N/A - N/A
Shares Out 233.12M
Stochastic %K 57%
Beta 0.61
Analysts Sell
Price Target $10.00

Company Profile

Invivyd, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's pipeline includes PEMGARDA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate, which is in preclinical studies for the prevention or treatment of COVID-19; and Adintrevimab that is in pha...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 819 0080
Website: invivyd.com
Address:
1601 Trapelo Road, Suite 178, Waltham, United States
OceanThunder7
OceanThunder7 Dec. 12 at 2:33 PM
$IVVD 2 coming up
0 · Reply
OceanThunder7
OceanThunder7 Dec. 11 at 2:39 PM
$IVVD Fill gap and I will go biggggggggggggggggg
1 · Reply
Doom_Gloom_AR
Doom_Gloom_AR Dec. 11 at 3:44 AM
$IVVD
0 · Reply
OceanThunder7
OceanThunder7 Dec. 10 at 9:09 PM
$TE $BBAI $IVVD $QQQ Crooks always get retail AH when they are handcuffed
0 · Reply
HawkSqueezers
HawkSqueezers Dec. 10 at 6:52 PM
Could SBDS be todays top micro float runner?! Looks like ticker SBDS could HALT UP again ! It's getting a lot of attention Only 700k shares outstanding - We have seen parabolic runs on these mico floats recently. Don't miss SBDS - It's starting to SQUEEZE up $CYCU $ATGL $IVVD $KTTA EM<F
0 · Reply
OceanThunder7
OceanThunder7 Dec. 10 at 3:26 PM
$QQQ $SPY 10-15% clip down starts at 2pm Place your bets accordingly at the Casino $BBAI $IVVD
0 · Reply
OceanThunder7
OceanThunder7 Dec. 10 at 3:10 PM
$IVVD Gap to 1.76 need to close somewhat
1 · Reply
SuperGreenToday
SuperGreenToday Dec. 10 at 10:43 AM
$IVVD Share Price: $2.48 Contract Selected: Jun 18, 2026 $0.5 Calls Buy Zone: $1.56 – $1.93 Target Zone: $2.86 – $3.49 Potential Upside: 73% ROI Time to Expiration: 189 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
bigkahunatrader
bigkahunatrader Dec. 10 at 5:25 AM
$IVVD Invivyd, Inc...TY-2 Cycle Trade...Stock Rating C-87 https://youtu.be/jjDo7Wk72Zs
0 · Reply
AbovetheGreenLine
AbovetheGreenLine Dec. 9 at 5:47 PM
Invivyd Inc. $IVVD is Don't Take a Loss! https://abovethegreenline.com/wp-content/uploads/2021/01/ST-1.jpg https://zpr.io/HC6vY2GtNNEh
0 · Reply
Latest News on IVVD
Invivyd to Participate at the 8th Annual Evercore Healthcare Conference

Nov 25, 2025, 7:01 AM EST - 17 days ago

Invivyd to Participate at the 8th Annual Evercore Healthcare Conference

Invivyd Announces Selection of Potential Best-In-Class RSV Antibody Candidate VBY329; Targeting 2H 2026 IND Readiness

Nov 24, 2025, 7:01 AM EST - 18 days ago

Invivyd Announces Selection of Potential Best-In-Class RSV Antibody Candidate VBY329; Targeting 2H 2026 IND Readiness

Invivyd: Maintaining Hold Rating With VYD2311 Alternative To Covid-19 Vaccination

Nov 18, 2025, 3:49 PM EST - 23 days ago

Invivyd: Maintaining Hold Rating With VYD2311 Alternative To Covid-19 Vaccination

Helmerich and Payne, Invivyd, Home Depot And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Nov 18, 2025, 8:23 AM EST - 24 days ago

Helmerich and Payne, Invivyd, Home Depot And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

HD HP

Invivyd Announces Pricing of $125 Million Public Offering of Common Stock and Pre-Funded Warrants

Nov 17, 2025, 10:40 PM EST - 24 days ago

Invivyd Announces Pricing of $125 Million Public Offering of Common Stock and Pre-Funded Warrants

Invivyd Announces Proposed Public Offering of Common Stock

Nov 17, 2025, 4:01 PM EST - 24 days ago

Invivyd Announces Proposed Public Offering of Common Stock

Invivyd, Inc. (IVVD) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 11:36 AM EST - 5 weeks ago

Invivyd, Inc. (IVVD) Q3 2025 Earnings Call Transcript

Invivyd Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Nov 6, 2025, 7:01 AM EST - 5 weeks ago

Invivyd Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Invivyd to Host Third Quarter 2025 Financial Results and Corporate Update Call on November 6, 2025

Nov 3, 2025, 4:01 PM EST - 5 weeks ago

Invivyd to Host Third Quarter 2025 Financial Results and Corporate Update Call on November 6, 2025

Invivyd, Inc. (IVVD) Discusses REVOLUTION Clinical Program and Development of VYD2311 Antibody for COVID Prevention Transcript

Oct 30, 2025, 11:36 PM EDT - 6 weeks ago

Invivyd, Inc. (IVVD) Discusses REVOLUTION Clinical Program and Development of VYD2311 Antibody for COVID Prevention Transcript

Invivyd to Host Webcast on the REVOLUTION Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID

Oct 28, 2025, 7:01 AM EDT - 6 weeks ago

Invivyd to Host Webcast on the REVOLUTION Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID

Invivyd Announces U.S. IND Clearance and Alignment with U.S. FDA on Pivotal Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID

Oct 6, 2025, 7:01 AM EDT - 2 months ago

Invivyd Announces U.S. IND Clearance and Alignment with U.S. FDA on Pivotal Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID

Invivyd Appoints Paul B. Bolno, M.D.

Sep 24, 2025, 4:01 PM EDT - 2 months ago

Invivyd Appoints Paul B. Bolno, M.D.

Invivyd Announces Appointment of Kristie Kuhl as Chief Communications Officer

Sep 17, 2025, 7:01 AM EDT - 3 months ago

Invivyd Announces Appointment of Kristie Kuhl as Chief Communications Officer

SPEAR Study Group to Present its Recommended Long COVID Antibody Study Design Featuring Invivyd's VYD2311 At RECOVER-TLC Workshop September 9-10, 2025

Sep 4, 2025, 7:01 AM EDT - 3 months ago

SPEAR Study Group to Present its Recommended Long COVID Antibody Study Design Featuring Invivyd's VYD2311 At RECOVER-TLC Workshop September 9-10, 2025

Invivyd: Superior COVID Prophylaxis; Eventual Winner Regardless Of Trump Admin Anti-Vaccine Actions

Aug 29, 2025, 9:55 AM EDT - 3 months ago

Invivyd: Superior COVID Prophylaxis; Eventual Winner Regardless Of Trump Admin Anti-Vaccine Actions

Invivyd to Participate in Upcoming Investor Conferences

Aug 27, 2025, 7:01 AM EDT - 3 months ago

Invivyd to Participate in Upcoming Investor Conferences

Invivyd Announces Closing of $57.5 Million Public Offering and Full Exercise of the Underwriter's Option to Purchase Additional Shares

Aug 22, 2025, 12:00 PM EDT - 3 months ago

Invivyd Announces Closing of $57.5 Million Public Offering and Full Exercise of the Underwriter's Option to Purchase Additional Shares

Invivyd Announces Pricing of $50 Million Public Offering of Common Stock and Pre-Funded Warrants

Aug 20, 2025, 11:58 PM EDT - 4 months ago

Invivyd Announces Pricing of $50 Million Public Offering of Common Stock and Pre-Funded Warrants

Invivyd Announces Continued Neutralizing Activity of PEMGARDA® (pemivibart) and VYD2311 Against Currently Dominant SARS-CoV-2 Variant XFG (“Stratus”)

Aug 18, 2025, 4:32 PM EDT - 4 months ago

Invivyd Announces Continued Neutralizing Activity of PEMGARDA® (pemivibart) and VYD2311 Against Currently Dominant SARS-CoV-2 Variant XFG (“Stratus”)

Invivyd Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Aug 14, 2025, 4:49 PM EDT - 4 months ago

Invivyd Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Invivyd Aligns with U.S. FDA on Rapid Pathway to Full Approval (BLA) of Vaccine Alternative Monoclonal Antibody VYD2311 to Protect American Adults and Adolescents from COVID-19

Aug 14, 2025, 4:47 PM EDT - 4 months ago

Invivyd Aligns with U.S. FDA on Rapid Pathway to Full Approval (BLA) of Vaccine Alternative Monoclonal Antibody VYD2311 to Protect American Adults and Adolescents from COVID-19

Scientist Dr. Akiko Iwasaki Joins SPEAR Study Group to Investigate Monoclonal Antibodies for Long COVID and COVID-19 Post-Vaccination Syndrome

Jul 23, 2025, 7:01 AM EDT - 5 months ago

Scientist Dr. Akiko Iwasaki Joins SPEAR Study Group to Investigate Monoclonal Antibodies for Long COVID and COVID-19 Post-Vaccination Syndrome

National Comprehensive Cancer Network® (NCCN®) Guidelines Recommend Monoclonal Antibodies for COVID-19 Prevention in People with Cancer; New Data Published in JAMA Oncology Underscore Severe Impact of COVID-19 on This Population

Jul 21, 2025, 7:05 AM EDT - 5 months ago

National Comprehensive Cancer Network® (NCCN®) Guidelines Recommend Monoclonal Antibodies for COVID-19 Prevention in People with Cancer; New Data Published in JAMA Oncology Underscore Severe Impact of COVID-19 on This Population

Invivyd and Leading Researchers Form SPEAR (Spike Protein Elimination and Recovery) Study Group to Assess the Effects of Monoclonal Antibody Therapy for Long COVID and COVID-19 Post-Vaccination Syndrome

Jul 2, 2025, 7:01 AM EDT - 5 months ago

Invivyd and Leading Researchers Form SPEAR (Spike Protein Elimination and Recovery) Study Group to Assess the Effects of Monoclonal Antibody Therapy for Long COVID and COVID-19 Post-Vaccination Syndrome

Invivyd Announces Positive Full Phase 1/2 Clinical Data for VYD2311, a Next Generation COVID-19 Monoclonal Antibody for Potential Use as a Non-Vaccine Preventative and for Treatment of Active Infection

Jun 26, 2025, 7:01 AM EDT - 6 months ago

Invivyd Announces Positive Full Phase 1/2 Clinical Data for VYD2311, a Next Generation COVID-19 Monoclonal Antibody for Potential Use as a Non-Vaccine Preventative and for Treatment of Active Infection

Invivyd Announces Publication of Landmark CANOPY Phase 3 PEMGARDA® (pemivibart) Clinical Trial; Results Underscore Strong Efficacy of Monoclonal Antibodies in Preventing COVID-19 in a Modern U.S. Population Against Relevant, Immune-Evasive SARS-CoV-2 Virus

May 27, 2025, 7:01 AM EDT - 7 months ago

Invivyd Announces Publication of Landmark CANOPY Phase 3 PEMGARDA® (pemivibart) Clinical Trial; Results Underscore Strong Efficacy of Monoclonal Antibodies in Preventing COVID-19 in a Modern U.S. Population Against Relevant, Immune-Evasive SARS-CoV-2 Virus

Invivyd Announces Inclusion of PEMGARDA® (pemivibart) in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas

May 23, 2025, 7:01 AM EDT - 7 months ago

Invivyd Announces Inclusion of PEMGARDA® (pemivibart) in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas

Invivyd Commends FDA Focus on Contemporary Evidence In Evaluating Medical Interventions To Prevent COVID-19

May 21, 2025, 9:30 AM EDT - 7 months ago

Invivyd Commends FDA Focus on Contemporary Evidence In Evaluating Medical Interventions To Prevent COVID-19

Invivyd, Inc. (IVVD) Q1 2025 Earnings Call Transcript

May 15, 2025, 11:08 AM EDT - 7 months ago

Invivyd, Inc. (IVVD) Q1 2025 Earnings Call Transcript

Invivyd Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 15, 2025, 7:01 AM EDT - 7 months ago

Invivyd Reports First Quarter 2025 Financial Results and Recent Business Highlights

Invivyd Files Citizen Petition Urging FDA to Focus on Monoclonal Antibodies For Endemic-Virus-Era COVID-19 Prevention, and to Re-Assess COVID-19 Vaccine Efficacy

May 14, 2025, 7:01 AM EDT - 7 months ago

Invivyd Files Citizen Petition Urging FDA to Focus on Monoclonal Antibodies For Endemic-Virus-Era COVID-19 Prevention, and to Re-Assess COVID-19 Vaccine Efficacy

Invivyd to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference

May 13, 2025, 7:01 AM EDT - 7 months ago

Invivyd to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference

Invivyd Announces New Pipeline Discovery Program Focused on Monoclonal Antibody Treatment for Measles

May 12, 2025, 7:01 AM EDT - 7 months ago

Invivyd Announces New Pipeline Discovery Program Focused on Monoclonal Antibody Treatment for Measles

Invivyd to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025

May 8, 2025, 7:01 AM EDT - 7 months ago

Invivyd to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025

Invivyd Announces $30M Non-dilutive Loan Facility with Silicon Valley Bank

Apr 21, 2025, 7:01 AM EDT - 8 months ago

Invivyd Announces $30M Non-dilutive Loan Facility with Silicon Valley Bank

Invivyd Appoints Ajay Royan, Founder of Mithril Capital, to its Board of Directors

Mar 26, 2025, 4:15 PM EDT - 9 months ago

Invivyd Appoints Ajay Royan, Founder of Mithril Capital, to its Board of Directors

Invivyd Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Recent Business Highlights

Mar 20, 2025, 8:01 AM EDT - 9 months ago

Invivyd Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Recent Business Highlights

Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Currently Dominant SARS-CoV-2 Variant LP.8.1

Mar 5, 2025, 7:05 AM EST - 10 months ago

Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Currently Dominant SARS-CoV-2 Variant LP.8.1

FDA Rejects Invivyd's Request To Expand Emergency Authorization For Preventive COVID-19 Antibody For Immunocompromised Patients

Feb 24, 2025, 9:20 AM EST - 10 months ago

FDA Rejects Invivyd's Request To Expand Emergency Authorization For Preventive COVID-19 Antibody For Immunocompromised Patients

FDA Declined Invivyd's Request to Expand Existing Emergency Use Authorization of PEMGARDA™ (pemivibart) to Include Treatment of Mild-to-Moderate COVID-19 For Immunocompromised Persons Who Have No Alternative Therapeutic Options; No Change to the Existing PEMGARDA EUA for Pre-Exposure Prophylaxis of COVID-19 in Certain Immunocompromised Patients

Feb 24, 2025, 7:05 AM EST - 10 months ago

FDA Declined Invivyd's Request to Expand Existing Emergency Use Authorization of PEMGARDA™ (pemivibart) to Include Treatment of Mild-to-Moderate COVID-19 For Immunocompromised Persons Who Have No Alternative Therapeutic Options; No Change to the Existing PEMGARDA EUA for Pre-Exposure Prophylaxis of COVID-19 in Certain Immunocompromised Patients

Invivyd to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025

Feb 10, 2025, 7:00 AM EST - 10 months ago

Invivyd to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025

Invivyd Announces Partnership with Pro Football Coach Jim Harbaugh to Elevate Awareness and Ongoing Impact of COVID-19: Common, Not A Cold

Feb 5, 2025, 9:30 AM EST - 11 months ago

Invivyd Announces Partnership with Pro Football Coach Jim Harbaugh to Elevate Awareness and Ongoing Impact of COVID-19: Common, Not A Cold

I See The Bull Case For Invivyd, But I'm Not Married To It

Feb 4, 2025, 3:55 PM EST - 11 months ago

I See The Bull Case For Invivyd, But I'm Not Married To It

Invivyd Announces Preliminary Fourth Quarter 2024 Financial Results, Strong Revenue Growth, and Reiterates Goal of Near-Term Profitability

Feb 3, 2025, 6:55 AM EST - 11 months ago

Invivyd Announces Preliminary Fourth Quarter 2024 Financial Results, Strong Revenue Growth, and Reiterates Goal of Near-Term Profitability

Invivyd Provides Another Positive SARS-CoV-2 Variant Data Analysis to Satisfy U.S. FDA's Gating Request for Completing Its Review of EUA Request for PEMGARDA™ (pemivibart) for the Treatment of Mild-to-Moderate COVID-19 in Certain Immunocompromised Patients

Jan 27, 2025, 7:01 AM EST - 11 months ago

Invivyd Provides Another Positive SARS-CoV-2 Variant Data Analysis to Satisfy U.S. FDA's Gating Request for Completing Its Review of EUA Request for PEMGARDA™ (pemivibart) for the Treatment of Mild-to-Moderate COVID-19 in Certain Immunocompromised Patients

Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variant XEC

Jan 10, 2025, 7:01 AM EST - 1 year ago

Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variant XEC

Invivyd, Inc. (IVVD) Q3 2024 Earnings Call Transcript

Nov 14, 2024, 2:15 PM EST - 1 year ago

Invivyd, Inc. (IVVD) Q3 2024 Earnings Call Transcript

Invivyd Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Nov 14, 2024, 7:05 AM EST - 1 year ago

Invivyd Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Invivyd Announces New England Journal of Medicine Publishes Letter to the Editor Highlighting Immunobridging Pathway Leading to PEMGARDA™ (pemivibart) Emergency Use Authorization; Comments on Adjacent Third-Party Letter to the Editor

Nov 14, 2024, 7:01 AM EST - 1 year ago

Invivyd Announces New England Journal of Medicine Publishes Letter to the Editor Highlighting Immunobridging Pathway Leading to PEMGARDA™ (pemivibart) Emergency Use Authorization; Comments on Adjacent Third-Party Letter to the Editor

OceanThunder7
OceanThunder7 Dec. 12 at 2:33 PM
$IVVD 2 coming up
0 · Reply
OceanThunder7
OceanThunder7 Dec. 11 at 2:39 PM
$IVVD Fill gap and I will go biggggggggggggggggg
1 · Reply
Doom_Gloom_AR
Doom_Gloom_AR Dec. 11 at 3:44 AM
$IVVD
0 · Reply
OceanThunder7
OceanThunder7 Dec. 10 at 9:09 PM
$TE $BBAI $IVVD $QQQ Crooks always get retail AH when they are handcuffed
0 · Reply
HawkSqueezers
HawkSqueezers Dec. 10 at 6:52 PM
Could SBDS be todays top micro float runner?! Looks like ticker SBDS could HALT UP again ! It's getting a lot of attention Only 700k shares outstanding - We have seen parabolic runs on these mico floats recently. Don't miss SBDS - It's starting to SQUEEZE up $CYCU $ATGL $IVVD $KTTA EM<F
0 · Reply
OceanThunder7
OceanThunder7 Dec. 10 at 3:26 PM
$QQQ $SPY 10-15% clip down starts at 2pm Place your bets accordingly at the Casino $BBAI $IVVD
0 · Reply
OceanThunder7
OceanThunder7 Dec. 10 at 3:10 PM
$IVVD Gap to 1.76 need to close somewhat
1 · Reply
SuperGreenToday
SuperGreenToday Dec. 10 at 10:43 AM
$IVVD Share Price: $2.48 Contract Selected: Jun 18, 2026 $0.5 Calls Buy Zone: $1.56 – $1.93 Target Zone: $2.86 – $3.49 Potential Upside: 73% ROI Time to Expiration: 189 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
bigkahunatrader
bigkahunatrader Dec. 10 at 5:25 AM
$IVVD Invivyd, Inc...TY-2 Cycle Trade...Stock Rating C-87 https://youtu.be/jjDo7Wk72Zs
0 · Reply
AbovetheGreenLine
AbovetheGreenLine Dec. 9 at 5:47 PM
Invivyd Inc. $IVVD is Don't Take a Loss! https://abovethegreenline.com/wp-content/uploads/2021/01/ST-1.jpg https://zpr.io/HC6vY2GtNNEh
0 · Reply
OceanThunder7
OceanThunder7 Dec. 9 at 3:03 PM
$IVVD I'll take a flyer at 1.95 lets gooooooooooooooo
0 · Reply
BiotechBonesaw
BiotechBonesaw Dec. 8 at 5:01 PM
$GPCR $KYMR $OCUL $IVVD great day for biotech! 🚀
0 · Reply
DaBullRunner
DaBullRunner Dec. 6 at 2:45 AM
HE JUST MADE OVER $100,000 AFTER RECENTLY JOINING MY WHATSAPP GROUP 🚨💰🤑💰🤑💰 Follow me on WhatsApp, Instagram, TikTok, and X will have access to my new WhatsApp group.. Make sure to WhatsApp me with your Stocktwits handle so I can identify you 🙏 Instagram: dabullrun ✅ TikTok: official.dbr.island ✅ X: dbr_says ✅ WhatsApp: +1-646-397-9559 ✅ $CYCU $APLT $IVVD $LAZR $MLSS see you tomorrow
0 · Reply
DaBullRunner
DaBullRunner Dec. 5 at 1:47 AM
HE JUST MADE OVER $100,000 AFTER RECENTLY JOINING MY WHATSAPP GROUP 🚨💰🤑💰🤑💰 Follow me on WhatsApp, Instagram, TikTok, and X will have access to my new WhatsApp group.. Make sure to WhatsApp me with your Stocktwits handle so I can identify you 🙏 Instagram: dabullrun ✅ TikTok: official.dbr.island ✅ X: dbr_says ✅ WhatsApp: +1-646-397-9559 ✅ $CYCU $APLT $IVVD $LAZR $MLSS see you tomorrow
0 · Reply
gb2017384
gb2017384 Dec. 4 at 8:25 PM
$IVVD BEING BULLISH=
0 · Reply
chimp_with_gun
chimp_with_gun Dec. 4 at 8:08 PM
$IVVD Not to worry - technicals on target for 3.5 by Feb 26, leaving aside any fundamentals' or data analysis
0 · Reply
gb2017384
gb2017384 Dec. 4 at 8:05 PM
$IVVD THIS IS WHAT WAITING GETS YOU!
0 · Reply
gb2017384
gb2017384 Dec. 4 at 7:56 PM
$IVVD
0 · Reply
gb2017384
gb2017384 Dec. 4 at 7:45 PM
$IVVD IS THIS WHAT WE BEEN WAITING FOR,IS THIS HOW WE GET REPAID,REALLY!
0 · Reply
gb2017384
gb2017384 Dec. 4 at 4:37 PM
$IVVD what's going on with this stupid stock now!
0 · Reply
DaBullRunner
DaBullRunner Dec. 4 at 2:26 AM
Join the team and bank with us 💰🤑💰🤑💰 Follow me on WhatsApp, Instagram, TikTok, and X will have access to my new WhatsApp group.. Make sure to WhatsApp me with your Stocktwits handle so I can identify you 🙏 Instagram: dabullrun ✅ TikTok: official.dbr.island ✅ X: dbr_says ✅ WhatsApp: +1-646-397-9559 ✅ $CYCU $APLT $IVVD $LAZR $MLSS see you tomorrow
1 · Reply
Doom_Gloom_AR
Doom_Gloom_AR Dec. 4 at 2:05 AM
$IVVD new cder chief is totally our buddy here. Fantastic news for us. https://www.statnews.com/2025/12/03/tracy-beth-hoeg-lead-center-for-drug-evaluation-and-research/
1 · Reply